ClinicalTrials.gg
CompletedNCT01697605Updated Dec 8, 2020

A Phase I Study of Oral BGJ398 in Asian Patients

A Phase 1 interventional study of BGJ398 in Tumor With Alterations of the FGF-R, sponsored by Novartis Pharmaceuticals. Completed at 8 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-12-08.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
9
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study will evaluate safety and tolerability to determine the Maximum tolerated dose (MTD) and/or Recommended dose (RD).

Read the detailed description

This is a multi-center, open label, dose finding, phase I study of oral single agent BGJ398, administered on a continuous once and/or twice daily schedule.

02

Conditions studied

  • Tumor With Alterations of the FGF-R

Keywords

  • Phase I, open-label, dose escalation, BGJ398, Japanese, Asian, FGF-R
03

In context

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.

Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with advanced solid tumors with FGF-R alteration
  • (ECOG) performance status 0-2
  • Adequate organ function

Exclusion criteria

Exclusion Criteria:

  • Patients with untreated and/or symptomatic Central Nerve System (CNS) disease
  • Pregnant or nursing (lactating) women

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    BGJ398

    Eligible participants received oral BGJ398 once daily or twice daily. Patients may continue treatment with BGJ398 until the patient experiences unacceptable toxicity or progressive disease.

    Drug: BGJ398

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence rate and category of dose limiting toxicities (DLTs)

    Maximum tolerated dose (MTD) and/or Recommended dose (RD) of single agent oral BGJ398

    Time frame: First cycle of 28 days

Secondary outcomes

  1. Frequency of all Adverse Events (AEs) and Serious Advers Events (SAEs)

    To characterize the safety and tolerability of oral BGJ398

    Time frame: From within 21 days of first treatment to 28 days after treatment discontinuation

  2. Changes in hematology and chemistry values

    hematology and chemistry values

    Time frame: From baseline to 28 days after treatment discontinuation

  3. Assessments of physical examinations, vital signs and electrocardiograms (ECGs)

    Time frame: Participants will be followed for the duration of treatment, an expected average of 24 weeks.

  4. Time vs. concentration profiles

    To determine the pharmacokinetic (PK) profiles (Cmax, AUC, Tmax, T1/2, etc) of oral BGJ398 including known pharmacologically active metabolites

    Time frame: 1 to 10 time points (0, 0.25, 1, 2, 3, 4, 6, 8, 12, 24 hours post-dose) up to 24 weeks

  5. Preliminary anti-tumor activity

    Assessed based on RECIST version 1.1

    Time frame: Participants will be followed for the duration of treatment, an expected average of 24 weeks.

  6. Best overall response (BOR)

    Assessed by investigator per RECIST version 1.1. BOR is the best response recorded until disease progression.

    Time frame: Participants will be followed for the duration of treatment, an expected average of 24 weeks.

  7. Overall response rate (ORR)

    Assessed by investigator per RECIST version 1.1. ORR is the proportion of patients with a best overall response of Complete Response (CR) or Partial Response (PR).

    Time frame: Participants will be followed for the duration of treatment, an expected average of 24 weeks.

  8. Progression-free survival (PFS)

    PFS is defined as the times from the date of first dose of BGJ398 to the date of the first documented disease progression, date of death due to any cause or until a new anticancer therapy is initiated, whichever occurs first.

    Time frame: From date of end of treatment until the date of progression, or date of death, or starting date of a new anticancer therapy, assessed up to 100 months.

  9. Duration of all Adverse Events (AEs)

    To characterize the safety and tolerability of oral BGJ398

    Time frame: From within 21 days of first treatment to 28 days after treatment discontinuation

  10. Duration of Serious Advers Events (SAEs)

    To characterize the safety and tolerability of oral BGJ398

    Time frame: From within 21 days of first treatment to 28 days after treatment discontinuation

  11. Severity of all Adverse Events (AEs)

    To characterize the safety and tolerability of oral BGJ398

    Time frame: From within 21 days of first treatment to 28 days after treatment discontinuation

  12. Severity of all Serious Advers Events (SAEs)

    To characterize the safety and tolerability of oral BGJ398

    Time frame: From within 21 days of first treatment to 28 days after treatment discontinuation

07

Study locations

8 sites
  • Novartis Investigative Site
    Guangzhou, Guangdong 51000, China
  • Novartis Investigative Site
    Chengdu, Sichuan 610041, China
  • Novartis Investigative Site
    Guangzhou, 510060, China
  • Nagoya University Hospital
    Nagoya-city, Aichi 466-8560, Japan
  • National Cancer Center Hospital East (NCEE)
    Kashiwa, Chiba 277-8577, Japan
  • Novartis Investigative Site
    Kobe-shi, Hyogo 650-0017, Japan
  • Novartis Investigative Site
    Sayama, Osaka 589 8511, Japan
  • Shizuoka Cancer Center
    Sunto-gun, Shizuoka 411-8777, Japan
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2012 to primary completion in Feb 2019, 75 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2012
First posted
Oct 2, 2012
StartActual
Oct 19, 2012
Primary completionActual
Feb 7, 2019
CompletionActual
Feb 7, 2019
Last update
Dec 8, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 8, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01697605
Responsible party
Sponsor
First posted
Oct 2, 2012
Start date
Oct 19, 2012
Primary completion
Feb 7, 2019
Completion
Feb 7, 2019
Last update
Dec 8, 2020

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Infigratinib

Start the discussion